Interferon alpha sublingual - Biolingus
Alternative Names: BL SLIT IILatest Information Update: 28 Oct 2024
At a glance
- Originator Biolingus
- Class Antineoplastics; Antivirals; Interferons
- Mechanism of Action Interferon replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported COVID 2019 infections; Influenza virus infections
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for preclinical development in COVID-2019-infections(Prevention) in Switzerland (Sublingual)
- 28 Oct 2024 No recent reports of development identified for preclinical development in Influenza-virus-infections(Prevention) in Switzerland (Sublingual)
- 22 Sep 2020 Interferon alpha - Biolingus is available for licensing as of 22 Sep 2020. http://www.biolingus.ch/index.html#partners